Bio-Rad Laboratories, Inc 8-K, filed Nov 4, 2026
Bio-Rad Laboratories, Inc. (BIO)
8-K
2026-11-04
For: 2026-11-04
View Original
Added on
November 04, 2026
About this 8-K
Bio-Rad Laboratories, Inc filed this 8-K on November 4, 2026.
Bio-Rad Laboratories, Inc. reported third-quarter 2026 net sales of $656.4 million, up 0.5% from $653.0 million. GAAP net income was $458.6 million, substantially reflecting the fair-market-value change in its Sartorius AG investment. AI summary
Items reported
- Item 2.02: Financial results
- Item 7.01: Regulation FD disclosure
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: November 4, 2026
(Date of earliest event reported)
(Exact name of registrant as specified in its charter)
Commission File Number: 001-07928
| (State or other jurisdiction of incorporation) | (I.R.S. Employer Identification No.) | |||||||
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | |||||
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act: | ||||||||||||||
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). | ||
| Emerging growth company | ||||||||
| If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. | ☐ | |||||||
ITEM 2.02 Results of Operations and Financial Condition
On November 4, 2026, Bio-Rad Laboratories, Inc. (the “Company”) announced its financial results for the quarter ended September 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this report.
The information set forth under Item 7.01, Regulation FD Disclosure, concerning the Supplemental Earnings Presentation (as defined therein) is incorporated herein by reference.
ITEM 7.01 Regulation FD Disclosure
Also on November 4, 2026, the Company posted supplemental earnings materials with respect to its financial results for the quarter ended September 30, 2026 to its website (the “Supplemental Earnings Presentation”), which can be accessed at www.bio-rad.com in the Investor Relations section under the subheading "Events & Presentations". A copy of the Supplemental Earnings Presentation is furnished as Exhibit 99.2 to this report.
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1 and Exhibit 99.2 attached hereto, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
ITEM 9.01 Financial Statements and Exhibits
| Exhibit Number | Description | |||||||
| 99.1 | ||||||||
| 99.2 | ||||||||
| 104.1 | Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document | |||||||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| BIO-RAD LABORATORIES, INC. | ||||||||||||||
| Date: | November 4, 2026 | By: | /s/ Roop K. Lakkaraju | |||||||||||
| Roop K. Lakkaraju | ||||||||||||||
| Executive Vice President, Chief Financial Officer | ||||||||||||||
Exhibit 99.1
Press Release
Bio-Rad Reports Third-Quarter 2026 Financial Results
HERCULES, Calif.—November 4, 2026 -- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2026.
Norman Schwartz, Bio-Rad’s Chief Executive Officer, stated: “Our third-quarter results reflect the steady progress we have been driving. We returned to currency-neutral revenue growth, led by Clinical Diagnostics and strong demand for our Droplet Digital™ PCR instruments. Excluding restructuring and impairment items, margins expanded, reflecting benefits of our transformation initiatives. The reprioritization of our R&D efforts is yielding new, differentiated products for our customers, and our progress gives us confidence in our 2026 outlook.”
| Financial Results Highlights | ||||||||
| (In millions, except per share data and percentages) | ||||||||
| GAAP Results | ||||||||
| Q3 2026 | Q3 2025 | |||||||
| Net sales | $ | 656.4 | $ | 653.0 | ||||
| Gross margin | 50.1 | % | 52.6 | % | ||||
| Income (loss) from operations | $ | (49.7) | $ | 65.3 | ||||
| Operating margin | (7.6) | % | 10.0 | % | ||||
| Net income (loss) | $ | 458.6 | $ | (341.9) | ||||
| Income (loss) per diluted share | $ | 17.02 | $ | (12.70) | ||||
| Net cash from operations | $ | 96.4 | $ | 120.9 | ||||
| Non-GAAP Results | ||||||||
| Q3 2026 | Q3 2025 | |||||||
| Net sales | $ | 656.4 | $ | 653.0 | ||||
| Gross margin | 54.5 | % | 53.5 | % | ||||
| Income from operations | $ | 83.7 | $ | 77.0 | ||||
| Operating margin | 12.8 | % | 11.8 | % | ||||
| Net income | $ | 71.5 | $ | 60.8 | ||||
| Income per diluted share | $ | 2.65 | $ | 2.26 | ||||
| Free cash flow | $ | 65.2 | $ | 89.2 | ||||
The non-GAAP financial measures shown in the table above and discussed below exclude certain items detailed later in this press release under the heading “Use of Non-GAAP Reporting”. A reconciliation between historical GAAP operating results and non-GAAP operating results is provided following the financial statements that are part of this press release.
Third-Quarter 2026 Results
Third-quarter 2026 total net sales were $656.4 million compared to $653.0 million reported for the third quarter of 2025, an increase of 0.5%. On a currency-neutral basis, sales increased 0.7 percent compared to the same period in 2025, driven by higher sales in Clinical Diagnostics segment.
Life Science segment net sales for the third quarter were $254.6 million, a decrease of 2.8 percent compared to the same period in 2025. On a currency-neutral basis, Life Science segment sales decreased 2.4 percent compared to the
1
same period in 2025. The currency-neutral year-over-year sales decrease was primarily driven by lower process chromatography sales and ongoing challenges in the academic research market partially offset by increased Droplet Digital™ PCR sales.
Clinical Diagnostics segment net sales for the third quarter were $401.8 million, an increase of 2.7 percent compared to the same period in 2025. On a currency-neutral basis, Clinical Diagnostics segment sales increased 2.8 percent compared to the same period in 2025. The currency-neutral year-over-year sales increase was primarily driven by growth in quality systems and diabetes products.
During the third quarter of 2026, the Company recognized a change in the fair market value of its investment in Sartorius AG, which substantially contributed to a net income of $458.6 million, or $17.02 per share, on a diluted basis, compared to a net loss of $(341.9) million, or $(12.70) per share, on a diluted basis, reported for the same period in 2025.
The effective tax rate for the third quarter of 2026 was 14.9 percent, compared to 20.7 percent for the same period in 2025. The effective tax rate reported in these periods was primarily affected by the change in fair market value of our equity securities, shifts in the geographical mix of earnings, and release of valuation allowance established with respect to our deferred tax assets.
The non-GAAP effective tax rate for the third quarter of 2026 was 21.4 percent, compared to 26.7 percent for the same period in 2025. The lower rate in 2026 was driven by geographical mix of earnings.
Full-Year 2026 Financial Outlook
For the full-year 2026, the Company continues to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent.
Conference Call and Webcast
Management will discuss the Company’s third quarter 2026 results and financial outlook in a conference call scheduled for 2:00 PM Pacific Time (5:00 PM Eastern Time) on November 4, 2026. To participate, dial (800) 715-9871 within the U.S., or (+1) (646) 307-1963 from outside the U.S., and provide access code: 9562470.
A live webcast of the conference call will also be available in the “Investor Relations” section of the Company’s website under “Events & Presentations” at investors.bio-rad.com. A replay of the webcast will be available for up to a year.
BIO-RAD and Droplet Digital PCR are trademarks of Bio-Rad Laboratories, Inc.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) is a leader in developing, manufacturing, and marketing a broad range of products for the life science research and clinical diagnostics markets. Based in Hercules, California, Bio-Rad operates a global network of research, development, manufacturing, and sales operations with approximately 7,100 employees and $2.6 billion in revenues in 2025. Our customers include universities, research institutions, hospitals, and biopharmaceutical companies, as well as clinical, food safety and environmental quality laboratories. Together, we develop innovative, high-quality products that advance science and save lives. To learn more, visit bio-rad.com
2
Forward-Looking Statements
This release may be deemed to contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements we make regarding estimated future financial performance or results; our progress giving us confidence in our 2026 outlook; and for the full-year 2026: continuing to expect non-GAAP, currency-neutral revenue to be in the range of a decline of approximately 3.0 percent to growth of approximately 0.5 percent, and an estimated non-GAAP operating margin of approximately 10.0 to 12.0 percent. Forward-looking statements generally can be identified by the use of forward-looking terminology such as, "expect,” "estimate," "continue," “remain,” "believe," "anticipate," “target,” "will," "project," "assume," “plan,” "may," "intend," or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. Such statements involve risks and uncertainties, which could cause actual results to vary materially from those expressed in or indicated by the forward-looking statements. These risks and uncertainties include risks relating to our international operations; global economic and geopolitical conditions; tariffs or other trade barriers; reductions in government funding or capital spending of our customers; the uncertain pace of the biopharma sector’s recovery; international legal and regulatory risks; our ability to develop and market new or improved products; our ability to compete effectively; foreign currency exchange fluctuations; our ability to integrate acquired companies, products or technologies into our company successfully; supply chain issues; product quality and liability issues; changes in the healthcare industry; and natural disasters and other catastrophic events beyond our control. For further information regarding the Company's risks and uncertainties, please refer to the "Risk Factors" and "Management’s Discussion and Analysis of Financial Condition and Results of Operations" in the Company's public reports filed with the Securities and Exchange Commission (the "SEC"), including the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the SEC. The Company cautions you not to place undue reliance on forward-looking statements, which reflect an analysis only and speak only as of the date hereof. Bio-Rad Laboratories, Inc. disclaims any obligation to update these forward-looking statements.
Investor Contact:
Ruben Argueta, Investor Relations
510-741-6104
ir@bio-rad.com
Media Contact:
Anna Gralinska, Corporate Communications
510-741-6643
cc@bio-rad.com
3
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Income (Loss)
(In millions, except number of shares, which are reflected in thousands, and per share data)
(Unaudited)
| Three Months Ended | Nine Months Ended | ||||||||||||||||||||||
| September 30, | September 30, | ||||||||||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||||||||||
| Net sales | $ | 656.4 | $ | 653.0 | $ | 1,899.5 | $ | 1,890.0 | |||||||||||||||
| Cost of goods sold | 327.8 | 309.6 | 915.7 | 895.3 | |||||||||||||||||||
| Gross profit | 328.6 | 343.4 | 983.8 | 994.7 | |||||||||||||||||||
| Selling, general and administrative expense | 257.1 | 206.8 | 681.5 | 623.3 | |||||||||||||||||||
| Research and development expense | 71.4 | 71.3 | 195.5 | 205.3 | |||||||||||||||||||
| Impairment of purchased intangibles | 49.8 | — | 49.8 | — | |||||||||||||||||||
| Income (loss) from operations | (49.7) | 65.3 | 57.0 | 166.1 | |||||||||||||||||||
| Interest expense | 12.3 | 12.3 | 36.7 | 36.9 | |||||||||||||||||||
| Foreign currency exchange gains, net | (2.1) | (2.9) | (4.7) | (4.5) | |||||||||||||||||||
| (Gains) losses from change in fair market value of equity securities and loan receivable | (588.2) | 495.3 | (308.0) | 129.1 | |||||||||||||||||||
| Other income, net | (10.4) | (8.3) | (58.0) | (61.7) | |||||||||||||||||||
| Income (loss) before income taxes | 538.7 | (431.1) | 391.0 | 66.3 | |||||||||||||||||||
| (Provision for) benefit from income taxes | (80.1) | 89.2 | (88.1) | (26.4) | |||||||||||||||||||
| Net income (loss) | $ | 458.6 | $ | (341.9) | $ | 302.9 | $ | 39.9 | |||||||||||||||
| Basic earnings (loss) per share: | |||||||||||||||||||||||
| Net income (loss) per basic share | $ | 17.13 | $ | (12.70) | $ | 11.29 | $ | 1.46 | |||||||||||||||
| Weighted average common shares - basic | 26,780 | 26,923 | 26,827 | 27,359 | |||||||||||||||||||
| Diluted earnings (loss) per share: | |||||||||||||||||||||||
| Net income (loss) per diluted share | $ | 17.02 | $ | (12.70) | $ | 11.25 | $ | 1.46 | |||||||||||||||
| Weighted average common shares - diluted | 26,945 | 26,923 | 26,923 | 27,369 | |||||||||||||||||||
Note: As a result of the net loss for the three months ended September 30, 2025, all potentially issuable common shares have been excluded from the diluted shares used in the computation of earnings per share as their effect was anti-dilutive.
4
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Balance Sheets
(In millions)
| September 30, 2026 | December 31, 2025 | ||||||||||
| (Unaudited) | |||||||||||
| Current assets: | |||||||||||
| Cash and cash equivalents | $ | 465.3 | $ | 529.8 | |||||||
| Short-term investments | 1,199.0 | 1,010.9 | |||||||||
| Accounts receivable, net | 422.6 | 460.6 | |||||||||
| Inventories, net | 783.9 | 740.7 | |||||||||
| Other current assets | 207.8 | 164.2 | |||||||||
| Total current assets | 3,078.6 | 2,906.2 | |||||||||
| Property, plant and equipment, net | 505.7 | 539.9 | |||||||||
| Operating lease right-of-use assets | 147.1 | 170.0 | |||||||||
| Goodwill, net | 573.0 | 579.8 | |||||||||
| Purchased intangibles, net | 104.4 | 174.3 | |||||||||
| Other investments | 6,273.2 | 6,103.6 | |||||||||
| Other assets | 101.1 | 102.7 | |||||||||
| Total assets | $ | 10,783.1 | $ | 10,576.5 | |||||||
| Current liabilities: | |||||||||||
| Accounts payable, accrued payroll and employee benefits | $ | 343.8 | $ | 301.3 | |||||||
| Current maturities of long-term debt and notes payable | 400.9 | 1.3 | |||||||||
| Income and other taxes payable | 37.8 | 36.6 | |||||||||
| Other current liabilities | 186.6 | 177.8 | |||||||||
| Total current liabilities | 969.1 | 517.0 | |||||||||
| Long-term debt, net of current maturities | 803.1 | 1,201.7 | |||||||||
| Other long-term liabilities | 1,407.9 | 1,404.2 | |||||||||
| Total liabilities | 3,180.1 | 3,122.9 | |||||||||
| Total stockholders’ equity | 7,603.0 | 7,453.6 | |||||||||
| Total liabilities and stockholders’ equity | $ | 10,783.1 | $ | 10,576.5 | |||||||
5
BIO-RAD LABORATORIES, INC.
Condensed Consolidated Statements of Cash Flows
(In millions)
(Unaudited)
| Nine Months Ended | |||||||||||
| September 30, | |||||||||||
| 2026 | 2025 | ||||||||||
| Cash flows from operating activities: | |||||||||||
| Cash received from customers | $ | 1,915.9 | $ | 1,958.7 | |||||||
| Cash paid to suppliers and employees | (1,607.8) | (1,511.4) | |||||||||
| Interest paid, net | (45.7) | (45.5) | |||||||||
| Income tax payments, net | (40.4) | (54.3) | |||||||||
| Other operating activities | 81.2 | 19.8 | |||||||||
| Net cash provided by operating activities | 303.2 | 367.3 | |||||||||
| Cash flows from investing activities: | |||||||||||
| (Payments for) proceeds from acquisitions, net of cash received | 1.1 | (218.5) | |||||||||
| Payments for purchases of marketable securities and investments | (677.7) | (530.5) | |||||||||
| Proceeds from sales and maturities of marketable securities and investments | 464.0 | 705.2 | |||||||||
| Payments for purchases of property, plant and equipment, net of proceeds from dispositions | (93.2) | (111.7) | |||||||||
| Net cash used in investing activities | (305.8) | (155.5) | |||||||||
| Cash flows from financing activities: | |||||||||||
Payments on long-term debt | (0.4) | (0.3) | |||||||||
| Payments for purchases of treasury stock | (79.3) | (295.5) | |||||||||
| Other financing activities | 6.5 | 9.3 | |||||||||
| Net cash used in financing activities | (73.2) | (286.5) | |||||||||
Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | 10.7 | (16.9) | |||||||||
| Net decrease in cash, cash equivalents and restricted cash | (65.1) | (91.6) | |||||||||
| Cash, cash equivalents and restricted cash at beginning of period | 532.2 | 489.8 | |||||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 467.1 | $ | 398.2 | |||||||
| Reconciliation of net income to net cash provided by operating activities: | |||||||||||
| Net income | $ | 302.9 | $ | 39.9 | |||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
| Depreciation and amortization | 123.2 | 122.9 | |||||||||
| Impairment of purchased intangibles | 49.8 | — | |||||||||
| Reduction in the carrying amount of right-of-use assets | 28.4 | 30.1 | |||||||||
| Share-based compensation | 45.0 | 42.1 | |||||||||
| (Gains) losses from change in fair market value of equity securities and loan receivable | (308.0) | 129.1 | |||||||||
| Changes in working capital | (35.0) | 4.5 | |||||||||
| Changes in deferred income taxes | 60.6 | (19.7) | |||||||||
| Other | 36.3 | 18.4 | |||||||||
| Net cash provided by operating activities | $ | 303.2 | $ | 367.3 | |||||||
6
Use of Non-GAAP Reporting
This press release includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate business performance, guide operating decisions, support forecasting and planning, and determine compensation. These measures exclude items outside normal operations, those difficult to forecast, isolated gains and losses not expected to recur predictably, related tax provisions or benefits, and significant discrete tax events. We believe these disclosures provide useful supplemental information that, while not a substitute for GAAP, enhance transparency, assist in evaluating operating results and future prospects in the same manner as management, and facilitate comparisons across periods and with peer companies.
7
BIO-RAD LABORATORIES, INC.
Reconciliation of GAAP financial measures to non-GAAP financial measures
(In millions, except number of shares, which are reflected in thousands, and per share data)
(Unaudited)
| Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
| September 30, 2026 | % of revenue | September 30, 2025 | % of revenue | September 30, 2026 | % of revenue | September 30, 2025 | % of revenue | ||||||||||||||||||||||||||||||||||||||||
| GAAP cost of goods sold | $ | 327.8 | $ | 309.6 | $ | 915.7 | $ | 895.3 | |||||||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | (4.5) | (6.6) | (15.1) | (15.5) | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring benefits (costs) | (24.7) | 0.6 | (24.5) | (4.1) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP cost of goods sold | $ | 298.6 | $ | 303.6 | $ | 876.1 | $ | 875.7 | |||||||||||||||||||||||||||||||||||||||
| GAAP gross profit | $ | 328.6 | 50.1% | $ | 343.4 | 52.6% | $ | 983.8 | 51.8% | $ | 994.7 | 52.6% | |||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | 4.5 | 6.6 | 15.1 | 15.5 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring (benefits) costs | 24.7 | (0.6) | 24.5 | 4.1 | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP gross profit | $ | 357.8 | 54.5% | $ | 349.4 | 53.5% | $ | 1,023.4 | 53.9% | $ | 1,014.3 | 53.7% | |||||||||||||||||||||||||||||||||||
| GAAP selling, general and administrative expense | $ | 257.1 | $ | 206.8 | $ | 681.5 | $ | 623.3 | |||||||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | (0.5) | (0.7) | (1.8) | (2.0) | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition related benefits (costs) | — | (0.6) | (0.2) | (3.4) | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring benefits (costs) | (41.4) | (2.4) | (42.2) | (20.3) | |||||||||||||||||||||||||||||||||||||||||||
| European Union’s IVDR | (1.1) | (0.9) | (3.4) | (3.1) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP selling, general and administrative expense | $ | 214.1 | $ | 202.2 | $ | 633.9 | $ | 594.5 | |||||||||||||||||||||||||||||||||||||||
| GAAP research and development expense | $ | 71.4 | $ | 71.3 | $ | 195.5 | $ | 205.3 | |||||||||||||||||||||||||||||||||||||||
| Acquisition related benefits (costs) | (0.3) | (0.4) | (0.7) | (0.4) | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring benefits (costs) | (11.1) | (0.7) | (9.4) | (13.7) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP research and development expense | $ | 60.0 | $ | 70.2 | $ | 185.4 | $ | 191.2 | |||||||||||||||||||||||||||||||||||||||
| GAAP impairment of purchased intangibles | $ | 49.8 | $ | — | $ | 49.8 | $ | — | |||||||||||||||||||||||||||||||||||||||
| Impairment of purchased intangibles | (49.8) | — | (49.8) | — | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP impairment of purchased intangibles | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||||||||||||||||||
| GAAP income (loss) from operations | $ | (49.7) | (7.6)% | $ | 65.3 | 10.0% | $ | 57.0 | 3.0% | $ | 166.1 | 8.8% | |||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | 5.0 | 7.3 | 16.9 | 17.5 | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition related (benefits) costs | 0.3 | 1.0 | 0.9 | 3.8 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring (benefits) costs | 77.2 | 2.5 | 76.1 | 38.1 | |||||||||||||||||||||||||||||||||||||||||||
| European Union’s IVDR | 1.1 | 0.9 | 3.4 | 3.1 | |||||||||||||||||||||||||||||||||||||||||||
| Impairment of purchased intangibles | 49.8 | — | 49.8 | — | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP income from operations | $ | 83.7 | 12.8% | $ | 77.0 | 11.8% | $ | 204.1 | 10.7% | $ | 228.6 | 12.1% | |||||||||||||||||||||||||||||||||||
8
| GAAP (gains) losses from change in fair market value of equity securities and loan receivable | $ | (588.2) | $ | 495.3 | $ | (308.0) | $ | 129.1 | |||||||||||||||||||||||||||||||||||||||
| Gains (losses) from change in fair market value of equity securities and loan receivable | 588.2 | (495.3) | 308.0 | (129.1) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP (gains) losses from change in fair market value of equity securities and loan receivable | $ | — | $ | — | $ | — | $ | — | |||||||||||||||||||||||||||||||||||||||
| GAAP other income, net | $ | (10.4) | $ | (8.3) | $ | (58.0) | $ | (61.7) | |||||||||||||||||||||||||||||||||||||||
| Gains (losses) on equity-method investments | (7.1) | (7.0) | (12.6) | (6.2) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP other income, net | $ | (17.5) | $ | (15.3) | $ | (70.6) | $ | (67.9) | |||||||||||||||||||||||||||||||||||||||
| GAAP income (loss) before income taxes | $ | 538.7 | $ | (431.1) | $ | 391.0 | $ | 66.3 | |||||||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | 5.0 | 7.3 | 16.9 | 17.5 | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition related (benefits) costs | 0.3 | 1.0 | 0.9 | 3.8 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring (benefits) costs | 77.2 | 2.5 | 76.1 | 38.1 | |||||||||||||||||||||||||||||||||||||||||||
| European Union’s IVDR | 1.1 | 0.9 | 3.4 | 3.1 | |||||||||||||||||||||||||||||||||||||||||||
| Impairment of purchased intangibles | 49.8 | — | 49.8 | — | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses from change in fair market value of equity securities and loan receivable | (588.2) | 495.3 | (308.0) | 129.1 | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses on equity-method investments | 7.1 | 7.0 | 12.6 | 6.2 | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP income before income taxes | $ | 91.0 | $ | 82.9 | $ | 242.7 | $ | 264.1 | |||||||||||||||||||||||||||||||||||||||
| GAAP (provision for) benefit from income taxes | $ | (80.1) | $ | 89.2 | $ | (88.1) | $ | (26.4) | |||||||||||||||||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments | 60.6 | (111.3) | 38.0 | (34.9) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP provision for income taxes | $ | (19.5) | $ | (22.1) | $ | (50.1) | $ | (61.3) | |||||||||||||||||||||||||||||||||||||||
| GAAP net income (loss) | $ | 458.6 | 69.9% | $ | (341.9) | (52.4)% | $ | 302.9 | 15.9% | $ | 39.9 | 2.1% | |||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | 5.0 | 7.3 | 16.9 | 17.5 | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition related (benefits) costs | 0.3 | 1.0 | 0.9 | 3.8 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring (benefits) costs | 77.2 | 2.5 | 76.1 | 38.1 | |||||||||||||||||||||||||||||||||||||||||||
| European Union’s IVDR | 1.1 | 0.9 | 3.4 | 3.1 | |||||||||||||||||||||||||||||||||||||||||||
| Impairment of purchased intangibles | 49.8 | — | 49.8 | — | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses from change in fair market value of equity securities and loan receivable | (588.2) | 495.3 | (308.0) | 129.1 | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses on equity-method investments | 7.1 | 7.0 | 12.6 | 6.2 | |||||||||||||||||||||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments | 60.6 | (111.3) | 38.0 | (34.9) | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP net income | $ | 71.5 | 10.9% | $ | 60.8 | 9.3% | $ | 192.6 | 10.1% | $ | 202.8 | 10.7% | |||||||||||||||||||||||||||||||||||
9
| GAAP diluted income (loss) per share | $ | 17.02 | $ | (12.70) | $ | 11.25 | $ | 1.46 | |||||||||||||||||||||||||||||||||||||||
| Amortization of purchased intangibles | 0.19 | 0.27 | 0.63 | 0.64 | |||||||||||||||||||||||||||||||||||||||||||
| Acquisition related (benefits) costs | 0.01 | 0.04 | 0.03 | 0.14 | |||||||||||||||||||||||||||||||||||||||||||
| Restructuring (benefits) costs | 2.87 | 0.09 | 2.83 | 1.39 | |||||||||||||||||||||||||||||||||||||||||||
| European Union’s IVDR | 0.04 | 0.03 | 0.13 | 0.11 | |||||||||||||||||||||||||||||||||||||||||||
| Impairment of purchased intangibles | 1.85 | — | 1.85 | — | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses from change in fair market value of equity securities and loan receivable | (21.83) | 18.38 | (11.44) | 4.72 | |||||||||||||||||||||||||||||||||||||||||||
| (Gains) losses on equity-method investments | 0.26 | 0.26 | 0.47 | 0.23 | |||||||||||||||||||||||||||||||||||||||||||
| Income tax effect of non-GAAP adjustments | 2.24 | (4.12) | 1.40 | (1.28) | |||||||||||||||||||||||||||||||||||||||||||
| Add back anti-dilutive shares | — | 0.01 | — | — | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP diluted income per share | $ | 2.65 | $ | 2.26 | $ | 7.15 | $ | 7.41 | |||||||||||||||||||||||||||||||||||||||
| GAAP diluted weighted average shares used in per share calculation | 26,945 | 26,923 | 26,923 | 27,369 | |||||||||||||||||||||||||||||||||||||||||||
| Shares included in non-GAAP net income per share, but excluded from GAAP net loss per share as they would have been anti-dilutive | — | 27 | — | — | |||||||||||||||||||||||||||||||||||||||||||
| Non-GAAP diluted weighted average shares used in per share calculation | 26,945 | 26,950 | 26,923 | 27,369 | |||||||||||||||||||||||||||||||||||||||||||
10
| Three Months Ended | Three Months Ended | Nine Months Ended | Nine Months Ended | ||||||||||||||||||||||||||||||||||||||||||||
| September 30, 2026 | September 30, 2025 | September 30, 2026 | September 30, 2025 | ||||||||||||||||||||||||||||||||||||||||||||
| Reconciliation of free cash flow: | |||||||||||||||||||||||||||||||||||||||||||||||
| GAAP net cash provided by operating activities | $ | 96.4 | $ | 120.9 | $ | 303.2 | $ | 367.3 | |||||||||||||||||||||||||||||||||||||||
| Payments for property, plant, and equipment | (31.2) | (31.7) | (93.2) | (111.8) | |||||||||||||||||||||||||||||||||||||||||||
| Free cash flow | $ | 65.2 | $ | 89.2 | $ | 210.0 | $ | 255.5 | |||||||||||||||||||||||||||||||||||||||
| Currency-Neutral Revenue | |||||||||||||||||||||||||||||||||||||||||||||||
| Life Science segment revenue | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue growth (decline), reported | (2.8) | % | 0.3 | % | (2.4) | % | — | % | |||||||||||||||||||||||||||||||||||||||
| Change due to foreign exchange | 0.4 | % | (1.8) | % | (1.5) | % | (0.3) | % | |||||||||||||||||||||||||||||||||||||||
| Currency-neutral revenue growth (decline) | (2.4) | % | (1.5) | % | (3.9) | % | (0.3) | % | |||||||||||||||||||||||||||||||||||||||
| Clinical Diagnostics segment revenue | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue growth (decline), reported | 2.7 | % | 0.6 | % | 2.4 | % | (0.8) | % | |||||||||||||||||||||||||||||||||||||||
| Change due to foreign exchange | 0.1 | % | (2.4) | % | (2.7) | % | (0.1) | % | |||||||||||||||||||||||||||||||||||||||
| Currency-neutral revenue growth (decline) | 2.8 | % | (1.8) | % | (0.3) | % | (0.9) | % | |||||||||||||||||||||||||||||||||||||||
| Total revenue | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue growth (decline), reported | 0.5 | % | 0.5 | % | 0.5 | % | (0.5) | % | |||||||||||||||||||||||||||||||||||||||
| Change due to foreign exchange | 0.2 | % | (2.2) | % | (2.2) | % | (0.2) | % | |||||||||||||||||||||||||||||||||||||||
| Currency-neutral revenue growth (decline) | 0.7 | % | (1.7) | % | (1.7) | % | (0.7) | % | |||||||||||||||||||||||||||||||||||||||
| Life Science segment revenue excluding process chromatography | |||||||||||||||||||||||||||||||||||||||||||||||
| Revenue growth (decline), reported | 2.0 | % | (6.0) | % | 1.3 | % | (5.0) | % | |||||||||||||||||||||||||||||||||||||||
| Change due to foreign exchange | 0.5 | % | (1.8) | % | (1.5) | % | (0.4) | % | |||||||||||||||||||||||||||||||||||||||
| Currency-neutral revenue growth (decline) | 2.5 | % | (7.8) | % | (0.2) | % | (5.4) | % | |||||||||||||||||||||||||||||||||||||||
11
Explanations of Non-GAAP Adjustments
Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisition. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations.
Acquisition-related amounts: we incur expenses or benefits with respect to certain items associated with our acquisitions, including professional fees for assistance with the transaction; valuation costs, integration costs, changes in the fair value of contingent consideration, and gains and losses on the settlement of pre-existing relationships with the acquired entity. We exclude such acquisition-related amounts because they have no direct correlation to the operation of our on-going business.
Restructuring charges: we incur costs associated with our restructuring actions, including termination benefits related to reductions in employee headcount and the closure or exit of facilities. We exclude the costs associated with these unique restructuring actions in order to provide comparability of our on-going operations with prior and future periods.
Impairment charges: we incur non-cash expenses associated primarily with impairment of long-lived assets including, but not limited to, goodwill, intangible assets and property, plant and equipment. By excluding these impairment charges, we believe this assists investors with evaluating our cash spending and analyzing our core operating performance period-over-period.
Gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: Our net income (loss) is impacted by gains and losses from change in fair market value of equity securities and loan receivable, and gain and losses associated with our equity-method investments included in Other income, net. These gains and losses arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. By excluding these gains and losses, we believe this assists investors in evaluating our core operating performance period-over-period.
Significant litigation amounts and legal costs: we may incur charges or benefits, in connection with litigation and other contingencies and legal costs unrelated to our core operations. We exclude these litigation amounts, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of our on-going business and operating results.
European Union’s IVDR: we incur incremental costs to comply with the European Union’s In Vitro Diagnostics Regulation (“IVDR”) for previously approved products.
Product portfolio rationalization related costs: we may incur charges associated with our product portfolio rationalization actions, including inventory write-downs, impairment of long-lived assets and accruals for contract termination or other exit-related costs. By excluding these one-time costs we believe this assists investors in evaluating our core operating performance period-over-period.
Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non-GAAP provision for income taxes. We also adjust for items for which the nature and/or tax jurisdiction requires the application of a specific tax rate or treatment.
From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management.
Other Key Metrics
Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The Company also uses this measure as an indication of the strength of the Company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure.
12
Currency-Neutral Revenue: we report percentage sales growth/decline in currency-neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.
2026 Financial Outlook
Forecasted non-GAAP operating margin excludes 83 basis points related to amortization of purchased intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments, future legal charges or benefits or future product portfolio rationalization related costs), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all.
13
Supplemental Earnings Results Presentation November 4, 2026 Third Quarter 2026 Financial Results
2 Some statements in this presentation may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, without limitation, statements regarding management’s goals, plans, and expectations, our future financial performance, our future financial projections, our growth strategy, and other matters. Forward looking statements generally can be identified by the use of forward-looking terminology such as, “anticipate,” “believe,” “expect,” “assume,” “continue,” “may,” “will,” “intend,” “estimate,” or similar expressions or the negative of those terms or expressions, although not all forward-looking statements contain these words. These statements are based on assumptions and expectations of future events that are subject to risks and uncertainties. Our actual results may differ materially from these plans and expectations. Undue reliance should not be placed on these forward-looking statements, and it is encouraged to review our SEC filings, where the risk factors in our business are discussed in detail. The forward- looking statements contained in this presentation reflect our views and assumptions only as of the date of this presentation. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change, so you should not rely on these forward-looking statements as representing our views as of any date other than the date of this presentation. In addition to financial measures prepared in accordance with generally accepted accounting principles (GAAP), this presentation also contains non-GAAP financial measures. Calculations of these measures, explanations of what these measures represent, the reasons why we believe these measures provide useful information to investors, a reconciliation of these measures to the most directly comparable GAAP measures, as applicable, and other information relating to these non-GAAP measures can be found in the Appendix at the end of this presentation. In addressing various financial metrics, the presentation describes some of the factors that impacted year-over-year performance. For additional factors that impacted year-over-year performance, please refer to our earnings release and our SEC filings, which are available in the “Investor Relations” section of our web site under the subheadings “Financials/ Financial Results” and “Quarterly Results." Safe Harbor Our Mission: Advance Science and Save Lives, Together
Gross Margin 50.1% Operating Margin* (7.6)% $96M Net Cash From Operations Revenue $656M 3 Q3 2026 GAAP Financial Results -250 bps -1,760 bps -$25M0.5% As Reported ** Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales. Change YoY Our Mission: Advance Science and Save Lives, Together * Operating Margin of (7.6)% includes restructuring charges of approximately $77 million and a non-cash impairment charge of approximately $50 million related to purchased intangible assets, reflecting the discontinuation and reprioritization of certain R&D programs. See the detailed reconciliation table in Bio-Rad’s third quarter 2026 earnings release, and the Appendix to this presentation. 0.7% CN**
Gross Margin* 54.5% Operating Margin* 12.8% $65M Free Cash Flow* Revenue $656M 4 Q3 2026 Non-GAAP Financial Results +100 bps +100 bps -$24M * Reconciliations to the comparable GAAP measure for the non-GAAP items shown above are detailed in the reconciliation table in Bio-Rad’s third quarter 2026 earnings release, and in the Appendix to this presentation. Our Mission: Advance Science and Save Lives, Together 0.5% As Reported Change YoY 0.7% CN** ** Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales.
5 Q3 2026 Business Segment Revenue and Geographic Mix $656M$656M Life Science 39% Clinical Diagnostics 61% Revenue by Business Segment APAC 21% Americas 45% EMEA 34% Revenue by Geography Our Mission: Advance Science and Save Lives, Together
6 Life Science Segment * Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales. Q3 2026 Revenue $255M -2.8% YoY -2.4% YoY CN* • Life Science segment revenue decreased in the Americas, partially offset by increased sales in EMEA and Asia Pacific.* • Excluding Process Chromatography, revenue grew 2.5%.* • Droplet Digital™ PCR franchise grew 7%, with instrument revenue up 20%+.* • Launched ChemiDoc™ Pro imaging system and expanded Foresight™ Pro pre-packed columns to Nuvia™ resins. APAC 20% Americas 47% EMEA 33% Revenue by Geography Our Mission: Advance Science and Save Lives, Together
7 Clinical Diagnostics Segment * Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales. Q3 2026 Revenue $402M +2.7% YoY +2.8% YoY CN* • Clinical Diagnostics segment revenue increased in the Americas and Asia Pacific, partially offset by decreased sales in EMEA.* • Growth led by quality systems and diabetes products.* APAC 22% Americas 44% EMEA 34% Revenue by Geography Our Mission: Advance Science and Save Lives, Together
8 Balance Sheet Highlights (In $ millions) December 31, 2025September 30, 2026 Inventories, net Investment in Sartorius AG Long-Term Debt, including current maturities Cash & Short-Term Investments $5,849 $5,669 $784 $741 $1,204 $1,203 $1,664 $1,541 Our Mission: Advance Science and Save Lives, Together (In $ millions)
9 Full-Year 2026 Outlook * Currency Neutral Revenue: We report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales. ** We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments or future legal charges or benefits, or future product portfolio rationalization related costs), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all. Non-GAAP Operating Margin** Free Cash Flow** Life Science Revenue CN* YoY Revenue CN* YoY Growth Clinical Diagnostics Revenue CN* YoY Non-GAAP Gross Margin** Our Mission: Advance Science and Save Lives, Together $290M to $340M -3.0% to +1.0% -3.0% to -1.0% -3.0% to +0.5% 10.0% to 12.0% 53.0% to 54.0%
Appendix This presentation includes GAAP financial measures as well as non-GAAP financial measures, which are not meant to be considered in isolation or as a substitute for comparable GAAP measures. We present certain non-GAAP financial measures to evaluate business performance, guide operating decisions, support forecasting and planning, and determine compensation. These measures exclude items outside normal operations, those difficult to forecast, isolated gains and losses not expected to recur predictably, related tax provisions or benefits, and significant discrete tax events. We believe these disclosures provide useful supplemental information that, while not a substitute for GAAP, enhance transparency, assist in evaluating operating results and future prospects in the same manner as management, and facilitate comparisons across periods and with peer companies. Use of Non-GAAP Financial Measures
11 Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures Our Mission: Advance Science and Save Lives, Together
12 Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures Our Mission: Advance Science and Save Lives, Together (continued)
13 (continued) Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures Our Mission: Advance Science and Save Lives, Together
14 Explanations of Non-GAAP Adjustments Amortization of purchased intangible assets: we do not acquire businesses and assets on a predictable cycle. The amount of purchase price allocated to purchased intangible assets and the terms of amortization can vary significantly and are unique to each acquisition. We believe that excluding amortization of purchased intangible assets allows the users of our financial statements to better review and understand the historic and current results of our operations. Acquisition-related amounts: we incur expenses or benefits with respect to certain items associated with our acquisitions, including professional fees for assistance with the transaction; valuation costs, integration costs, changes in the fair value of contingent consideration, and gains and losses on the settlement of pre-existing relationships with the acquired entity. We exclude such acquisition-related amounts because they have no direct correlation to the operation of our on-going business. Restructuring charges: we incur costs associated with our restructuring actions, including termination benefits related to reductions in employee headcount and the closure or exit of facilities. We exclude the costs associated with these unique restructuring actions in order to provide comparability of our on-going operations with prior and future periods. Impairment charges: we incur non-cash expenses associated primarily with impairment of long-lived assets including, but not limited to, goodwill, intangible assets and property, plant and equipment. By excluding these impairment charges, we believe this assists investors with evaluating our cash spending and analyzing our core operating performance period-over-period. Gains and losses from change in fair market value of equity securities and loan receivable, and gains and losses on equity-method investments: Our net income (loss) is impacted by gains and losses from change in fair market value of equity securities and loan receivable, and gain and losses associated with our equity-method investments included in Other income, net. These gains and losses arise from unforeseen circumstances and/or often occur outside of the ordinary course of our on-going business. By excluding these gains and losses, we believe this assists investors in evaluating our core operating performance period-over-period. Significant litigation amounts and legal costs: we may incur charges or benefits, in connection with litigation and other contingencies and legal costs unrelated to our core operations. We exclude these litigation amounts, when significant, as well as legal costs associated with significant legal matters, because we do not believe they are reflective of our on-going business and operating results. European Union’s IVDR: we incur incremental costs to comply with the European Union’s In Vitro Diagnostics Regulation (“IVDR”) for previously approved products. Product portfolio rationalization related costs: we may incur charges associated with our product portfolio rationalization actions, including inventory write-downs, impairment of long-lived assets and accruals for contract termination or other exit-related costs. By excluding these one-time costs we believe this assists investors in evaluating our core operating performance period-over-period. Income tax expense: we estimate the tax effect of the excluded items identified above to determine a non-GAAP annual effective tax rate applied to the pretax amount in order to calculate the non- GAAP provision for income taxes. From time to time in the future, there may be other items excluded if we believe that doing so is consistent with the goal of providing useful information to investors and management. Our Mission: Advance Science and Save Lives, Together
15 Other Key Metrics Free Cash Flow: we report free cash flow, which is operating cash flow excluding net capital expenditures, to provide a view of the continuing operations’ ability to generate cash for acquisitions and other investing and financing activities. The company also uses this measure as an indication of the strength of the company. Free cash flow is not a measure of cash available for discretionary expenditures since we have certain non-discretionary obligations such as debt service that are not deducted from the measure. Currency Neutral Revenue: we report percentage sales growth in currency neutral amounts by calculating translated prior period sales in each local currency using the current period’s monthly average foreign exchange rates for that currency and comparing that to current period sales. Our Mission: Advance Science and Save Lives, Together
16 2026 Financial Outlook Forecasted non-GAAP operating margin excludes 83 basis points related to amortization of purchase intangibles. Forecasted non-GAAP operating margin does not reflect future gains and charges that are inherently difficult to predict and estimate due to their unknown timing, effect and/or significance, such as foreign currency fluctuations, future gains or losses associated with certain legal matters, acquisitions and restructuring activities. We do not provide a reconciliation of our non-GAAP financial expectations to expectations for the most comparable GAAP measure because the amount and timing of many future charges that impact these measures (such as amortization of future acquisition-related intangible assets, future acquisition-related expenses and benefits, future restructuring charges, future asset impairment charges, future valuation changes of equity-owned securities, future gains and losses on equity-method investments, future legal charges or benefits or future product portfolio rationalization related costs), which could be material, are variable, uncertain, or out of our control and therefore cannot be reasonably predicted without unreasonable effort, if at all. Our Mission: Advance Science and Save Lives, Together